CLL cell apoptosis induced by nitric oxide synthase inhibitors: Correlation with lipid solubility and NOS1 dissociation constant

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1061-1070

  Levesque, Marc C ^a   Ghosh, Dipak K ^a   Beasley, Bethany E ^a   Chen, Youwei ^a   Volkheimer, Alicia D ^a   O'Loughlin, Charles W ^a   Gockerman, Jon P ^a   Moore, Joseph O ^a   Weinberg, J Brice ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Chronic lymphocytic leukemia (CLL); Human; Nitric oxide; Nitric oxide synthase type I

Indexed keywords

1 (2 TRIFLUOROMETHYLPHENYL)IMIDAZOLE; 2 AMINO 5,6 DIHYDRO 6 METHYL 4H 1,3 THIAZINE; 2 METHYLISOTHIOUREA SULFATE; 3 BROMO 7 NITROINDAZOLE; 7 NITROINDAZOLE; ARR 17477; GUANIDINOETHYLDISULFIDE; MERCAPTOETHYLGUANIDINE SODIUM SUCCINATE; N (4 AMINO 5[AMINOETHYL]AMINOPENTYL) N NITROGUANIDINE; N 5 1 IMINO 3 BUTENYLORNITHINE; N 6 (1 IMINOETHYL) LYSINE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N [4 (2 ((3 CHLOROPHENYLMETHYL)AMINO)ETHYL)PHENYL] 2 THIOPHECARBOXAMIDINE HYDROCHLORIDE; N PROPYLARGININE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; S (3 AMINOPROPYL)PSEUDOTHIOUREA; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; S ETHYL N [4 (TRIFLUOROMETHYL)PHENYL]ISOTHIOUREA; S ETHYLISOTHIOUREA; S,S' [1,3 PHENYLENE BIS(1,2 ETHANEDIYL)]BIS ISOTHIOUREA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL DEATH; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIPID SOLUBILITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DNA PRIMERS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPID METABOLISM; NITRIC OXIDE SYNTHASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLUBILITY;

EID: 41949096676     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.026     Document Type: Article

References (31)

1. Caligaris-Cappio F., and Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17 1 (1999) 399-408
2. Kuppers R., Klein U., Hansmann M.L., and Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 341 20 (1999) 1520-1529
3. Zhao H.X., Dugas N., Mathiot C., Delmer A., Dugas B., Sigaux F., et al. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92 3 (1998) 1031-1043
4. Levesque M.C., Misukonis M.A., O'Loughlin C.W., Chen Y., Beasley B.E., Wilson D.L., et al. IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. Leukemia 17 (2003) 442-450
5. Hetts S.W. To die or not to die: an overview of apoptosis and its role in disease. JAMA 279 4 (1998) 300-307
6. McConkey D.J., Chandra J., Wright S., Plunkett W., McDonnell T.J., Reed J.C., et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156 7 (1996) 2624-2630
7. Pepper C., Hoy T., and Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 76 7 (1997) 935-938
8. Bellosillo B., Dalmau M., Colomer D., and Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 89 9 (1997) 3378-3384
9. Genaro A.M., Hortelano S., Alvarez A., Martinez C., and Bosca L. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 95 4 (1995) 1884-1890
10. Dimmeler S., Haendeler J., Nehls M., and Zeiher A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 185 4 (1997) 601-607
11. Li J., Billiar T.R., Talanian R.V., and Kim Y.M. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240 2 (1997) 419-424
12. Mohr S., Zech B., Lapetina E.G., and Brune B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem Biophys Res Commun 238 2 (1997) 387-391
13. Mannick J.B., Hausladen A., Liu L., Hess D.T., Zeng M., Miao Q.X., et al. Fas-induced caspase denitrosylation. Science 284 5414 (1999) 651-654
14. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 329 27 (1993) 2002-2012
15. Bredt D.S., and Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63 (1994) 175-195
16. Barouch L.A., Harrison R.W., Skaf M.W., Rosas G.O., Cappola T.P., Kobeissi Z.A., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416 6878 (2002) 337-339
17. Ghafourifar P., and Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci 26 4 (2005) 190-195
18. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97 (1968) 77-89
19. Levesque M.C., O'Loughlin C.W., and Weinberg J.B. Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture. Leukemia 15 (2001) 1305-1307
20. Fedorov R., Hartmann E., Ghosh D.K., and Schlichting I. Structural basis for the specificity of the nitric-oxide synthase inhibitors W1400 and N-omega-propyl-l-Arg for the inducible and neuronal isoforms. J Biol Chem 278 46 (2003) 45818-45825
21. Fedorov R., Vasan R., Ghosh D.K., and Schlichting I. Structures of nitric oxide synthase isoforms complexed with the inhibitor AR-R17477 suggest a rational basis for specificity and inhibitor design. Proc Natl Acad Sci USA 101 16 (2004) 5892-5897
22. Weinberg J.B., Misukonis M.A., Shami P.J., Mason S.N., Sauls D.L., Dittman W.A., et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86 3 (1995) 1184-1195
23. Ghosh D.K., Wu C., Pitters E., Moloney M., Werner E.R., Mayer B., et al. Characterization of the inducible nitric oxide synthase oxygenase domain identifies a 49 amino acid segment required for subunit dimerization and tetrahydrobiopterin interaction. Biochemistry 36 35 (1997) 10609-10619
24. Chiorazzi N., Rai K.R., and Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352 8 (2005) 804-815
25. Mannick J.B., Asano K., Izumi K., Kieff E., and Stamler J.S. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79 7 (1994) 1137-1146
26. Mendes R.V., Martins A.R., de Nucci G., Murad F., and Soares F.A. Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology 39 2 Aug (2001) 172-178
27. Pou S., Pou W.S., Bredt D.S., Snyder S.H., and Rosen G.M. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 267 34 (1992) 24173-24176
28. Xia Y., Dawson V.L., Dawson T.M., Snyder S.H., and Zweier J.L. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 93 13 (1996) 6770-6774
29. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 5 Pt 1 (1996) C1424-C1437
30. Matter H., Kumar H.S., Fedorov R., Frey A., Kotsonis P., Hartmann E., et al. Structural analysis of isoform-specific inhibitors targeting the tetrahydrobiopterin binding site of human nitric oxide synthases. J Med Chem 48 15 (2005) 4783-4792
31. Vallance P., and Leiper J. Blocking NO synthesis: how, where and why?. Nat Rev Drug Discov 1 12 (2002) 939-950